Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Mol Cancer Ther. 2013 Mar;12(3):314-25. doi: 10.1158/1535-7163.MCT-12-0869. Epub 2013 Jan 11.
Tumor suppressor p53 is a multifunctional transcription factor that regulates diverse cell fates, including apoptosis and autophagy in tumor biology. p53 overexpression enhances the antitumor activity of oncolytic adenoviruses; however, the molecular mechanism of this occurrence remains unclear. We previously developed a tumor-specific replication-competent oncolytic adenovirus, OBP-301, that kills human osteosarcoma cells, but some human osteosarcoma cells were OBP-301-resistant. In this study, we investigated the antitumor activity of a p53-expressing oncolytic adenovirus, OBP-702, and the molecular mechanism of the p53-mediated cell death pathway in OBP-301-resistant human osteosarcoma cells. The cytopathic activity of OBP-702 was examined in OBP-301-sensitive (U2OS and HOS) and OBP-301-resistant (SaOS-2 and MNNG/HOS) human osteosarcoma cells. The molecular mechanism in the OBP-702-mediated induction of two cell death pathways, apoptosis and autophagy, was investigated in OBP-301-resistant osteosarcoma cells. The antitumor effect of OBP-702 was further assessed using an orthotopic OBP-301-resistant MNNG/HOS osteosarcoma xenograft tumor model. OBP-702 suppressed the viability of OBP-301-sensitive and -resistant osteosarcoma cells more efficiently than OBP-301 or a replication-deficient p53-expressing adenovirus (Ad-p53). OBP-702 induced more profound apoptosis and autophagy when compared with OBP-301 or Ad-p53. E1A-mediated miR-93/106b upregulation induced p21 suppression, leading to p53-mediated apoptosis and autophagy in OBP-702-infected cells. p53 overexpression enhanced adenovirus-mediated autophagy through activation of damage-regulated autophagy modulator (DRAM). Moreover, OBP-702 suppressed tumor growth in an orthotopic OBP-301-resistant MNNG/HOS xenograft tumor model. These results suggest that OBP-702-mediated p53 transactivation is a promising antitumor strategy to induce dual apoptotic and autophagic cell death pathways via regulation of miRNA and DRAM in human osteosarcoma cells.
肿瘤抑制因子 p53 是一种多功能转录因子,可调节多种细胞命运,包括肿瘤生物学中的细胞凋亡和自噬。p53 过表达增强了溶瘤腺病毒的抗肿瘤活性;然而,这种现象的分子机制尚不清楚。我们之前开发了一种肿瘤特异性复制型溶瘤腺病毒 OBP-301,它可以杀死人骨肉瘤细胞,但一些人骨肉瘤细胞对 OBP-301 具有抗性。在这项研究中,我们研究了表达 p53 的溶瘤腺病毒 OBP-702 的抗肿瘤活性,以及 OBP-301 耐药的人骨肉瘤细胞中 p53 介导的细胞死亡途径的分子机制。在 OBP-301 敏感(U2OS 和 HOS)和 OBP-301 耐药(SaOS-2 和 MNNG/HOS)人骨肉瘤细胞中检查了 OBP-702 的细胞病变活性。在 OBP-301 耐药骨肉瘤细胞中研究了 OBP-702 介导的两种细胞死亡途径(细胞凋亡和自噬)诱导的分子机制。使用 OBP-301 耐药 MNNG/HOS 骨肉瘤异种移植肿瘤模型进一步评估了 OBP-702 的抗肿瘤作用。与 OBP-301 或复制缺陷型 p53 表达腺病毒(Ad-p53)相比,OBP-702 更有效地抑制 OBP-301 敏感和耐药骨肉瘤细胞的活力。与 OBP-301 或 Ad-p53 相比,OBP-702 诱导更明显的细胞凋亡和自噬。E1A 介导的 miR-93/106b 上调诱导 p21 抑制,导致 OBP-702 感染细胞中 p53 介导的细胞凋亡和自噬。p53 过表达通过激活损伤调节自噬调节剂(DRAM)增强了腺病毒介导的自噬。此外,OBP-702 抑制了 OBP-301 耐药 MNNG/HOS 异种移植肿瘤模型中的肿瘤生长。这些结果表明,OBP-702 介导的 p53 反式激活通过调节 miRNA 和 DRAM 是一种很有前途的抗肿瘤策略,可诱导人骨肉瘤细胞中的双重凋亡和自噬细胞死亡途径。